Providing a
clear picture.

Supporting patient care

At Mayo Clinic, we offer a comprehensive approach to neuro-oncology testing that focuses on the best outcomes for the patient. Our advanced genetic testing combines molecular and cytogenetic analysis to complement standard morphological and histological assessment. This maximizes the amount of available information, and provides a clear picture of the diagnosis, prognosis, and treatment options. 


A complete assessment


Actionable answers


A clear diagnosis


By performing immunohistochemical, molecular, and cytogenetic
analysis on all patients, our testing approach provides a more
complete assessment of the patient’s diagnosis, prognosis, and
therapy options.

Broad molecular and cytogenetic information is needed for all
patients in order to select the most appropriate treatment options,
whether standard, off-label, or clinical trial.

Understanding specific molecular markers is necessary to making
a diagnosis that meets classification guidelines and can guide
treatment decisions and therapeutic timelines.

Comprehensive genetic profiling for
brain tumors

Mayo Clinic is recognized worldwide for providing care for complex diseases including brain tumors. With rapid technological advancements and medical discoveries, the standard approach to genetic testing is evolving. In a clinical study of adult glioma patients, comprehensive molecular and cytogenetic analysis resulted in significant, and sometimes unexpected, patient impact.

Clinical Relevance: Findings in Glioma Patients


In a Mayo Clinic study of adult glioma patients, comprehensive molecular and cytogenetic analysis resulted in
a significant positive impact on patients. Of 400 patients seen, 75% received diagnostic, prognostic,
and/or predictive information.

75%

of patients received one or more clinically actionable findings as a result of comprehensive molecular and cytogenetic testing.

45%

of cases reported diagnostic findings


34%

of cases reported prognostic findings


54%

of cases reported predictive findings


Need content here if we want a feature block.


A Test in Focus

Featured content here.

Additional Resources

Webinar - Molecular grouping of gliomas: clinical implications and utility

The "Specialty Testing" webinar, presented by Robert Jenkins, M.D., will briefly cover the current knowledge concerning the molecular genetic classification of adult gliomas.